PubAg

Main content area

Anti‐Disuse Osteoporosis Activity of a Complex of Calcium‐Binding Peptide from Auricularia auricula Protein Hydrolysates

Author:
Qu, Hang, Yi, Juanjuan, Gao, Xin, Zhao, Haitian, Wang, Zhenyu
Source:
Journal of food science 2019 v.84 no.7 pp. 1909-1919
ISSN:
0022-1147
Subject:
Auricularia auricula, acid phosphatase, alkaline phosphatase, animal models, blood serum, bone density, bone resorption, calcium, calcium carbonate, developmental orthopedic disease, gene expression regulation, genes, in vitro studies, interleukin-1, interleukin-6, mice, mineral content, neoplasms, osteoblasts, osteoporosis, patients, protective effect, protein hydrolysates, risk reduction, tail, tumor necrosis factor-alpha
Abstract:
Osteoporosis is a common metabolic bone disease that is often seen in bedridden patients and astronauts. Long‐term bed rest and nonweight bearing tend to induce disuse osteoporosis. Calcium supplements are commonly used to help treat disuse osteoporosis along with medications, most of which are calcium carbonate based, but they have poor absorption effects. In this study, we prepared a novel Auricularia auricula peptide–calcium complex (AP–Ca) and evaluated its protective effects on disuse osteoporosis. In vitro assays showed that AP–Ca significantly increased the contents of calcium (P < 0.05) and the activity of alkaline phosphatase (AKP; P < 0.05) of osteoblasts cultured in a two‐dimensional‐rotating wall vessel. Meanwhile, supplementation with AP–Ca also inhibited the production of pro‐inflammatory factors induced by the loss of stress, especially TNF‐α (P < 0.05). In vivo, a mouse tail suspension (TS) model was established, and the results showed that AP–Ca helped to improve bone mineral density, bone mineral content, and bone organic content in TS mice and effectively alleviated the alteration of enzymes related to bone metabolism, including AKP (P < 0.05) and serum tartrate‐resistant acid phosphatase (P < 0.05), to avoid more serious bone loss induced by TS. Furthermore, we found that AP–Ca downregulated the bone resorption‐associated pro‐inflammatory genes interleukin‐1 (IL‐1), tumor necrosis factor‐α, and IL‐6 by 59.53 ± 3.55%, 48.01 ± 5.68%, and 40.00 ± 5.89%, respectively (P < 0.05). In conclusion, AP–Ca showed potential to suppress bone loss induced by disuse and might be considered a new alternative to reduce the risk of disuse osteoporosis. PRACTICAL APPLICATION: This peptide–calcium complex supplement exhibited protective effects on the bone loss induced by disuse, which provided a new alternative for patients and astronauts to reduce the risk of disuse osteoporosis.
Agid:
6541297